<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160822</url>
  </required_header>
  <id_info>
    <org_study_id>CACZ885C2201</org_study_id>
    <secondary_id>2009-015017-48</secondary_id>
    <nct_id>NCT01160822</nct_id>
  </id_info>
  <brief_title>To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee</brief_title>
  <official_title>A Randomized, Double Blind, Placebo and Naproxen Controlled, Multi-center, Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine whether, in patients with mild to moderate knee
      osteoarthritis, canakinumab is safe and tolerable when injected intra-articularly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, parallel group, placebo controlled 18 weeks study,
      consisting of two parts:

        1. Part A: an ascending single dose part in which the safety and tolerability of up to 4
           different canakinumab doses are studied (starting dose 150 mg, maximum dose 600 mg).

        2. Part B: a double-dummy, active-controlled, parallel design part in which the pain
           reduction of the canakinumab dose selected from part A is studied in comparison to
           Placebo and Naproxen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of Participants With Intolerance Events</measure>
    <time_frame>Baseline to Day 3</time_frame>
    <description>An intolerance event is defined as an acute inflammatory reaction, characterized by a 30 mm increase in pain (on a 100 mm visual analog scale (VAS) and associated with a new or worsened synovial fluid effusion within 3 days following the intra-articular (i.a.) injection. If baseline VAS pain score is ≥ 70 mm, an intolerance event is defined as an increase in pain by 20 mm on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection. If baseline VAS pain score is ≥ 80 mm, an intolerance event is defined as an increase in pain by 10 mm on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection. If baseline pain score is ≥ 90 mm, an intolerance event is defined as the patients experiencing an unspecified increase in pain on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline to Day 4 in Pain Using 100 mm Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline and Day 4</time_frame>
    <description>After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm). A negative change from Baseline score indicates improvement.
Results are from a Bayesian analysis of covariance (ANCOVA) model, fitting baseline pain VAS score as a covariate, time by treatment as fixed effects, region and subject as random effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change From Baseline to Week 4 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The Western Ontario and McMaster osteoarthritis Index (WOMAC) pain subscale asks patients to rate pain in the index knee joint in the last 48 hours doing different activities on a scale from none (0) to extreme pain (4). The answers are summed and the total pain subscale score ranges from 0 to 20, where higher scores indicate more pain. A negative change from Baseline score indicates improvement.
Results are from a Bayesian ANCOVA model, fitting baseline WOMAC pain score as a covariate, time by treatment as fixed effects, region and patient as random effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in Pain Using 100 mm Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline and Weeks 4, 8 and 12</time_frame>
    <description>After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm).
Results are from a Bayesian ANCOVA model, fitting baseline pain VAS score as a covariate, time by treatment as fixed effects, region and patient as random effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Percentage of Responders in the Pain 100 mm Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, Day 4, Weeks 1, 2, 4, 8 and 12</time_frame>
    <description>A responder is defined as a participant with a 50% or greater reduction from baseline on the VAS scale for pain assessment. After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change From Baseline in WOMAC Pain, Stiffness and Physical Function Subscales</measure>
    <time_frame>Baseline and Weeks 4, 8 and 12</time_frame>
    <description>The WOMAC consists of 3 subscales:
The Pain subscale asks patients to rate pain in the index knee joint in the last 48 hours during walking, using stairs, in bed, sitting or lying, and standing on a scale from none (0) to extreme pain (4). The answers are summed and the total pain subscale score ranges from 0-20.
The Stiffness subscale assesses stiffness in the index knee joint during the last 48 hours doing different activities on a scale from none (0) to extreme stiffness (4). The total stiffness subscale score ranges from 0-8.
The Physical Function subscale assesses difficulty performing daily physical activities during the last 48 hours on a scale from none (0) to extreme difficulty (4). The total physical function subscale score ranges from 0-68.
Higher scores indicate more pain/stiffness/difficulty. Results are from a Bayesian ANCOVA model, with baseline WOMAC score as a covariate, time by treatment as fixed effects, region and patient as random effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of Participants Who Used Rescue Analgesic During Study</measure>
    <time_frame>Day 4, Weeks 1, 2, 4, 8 and 12</time_frame>
    <description>Participants were permitted to take oral rescue medication (Acetaminophen ≤ 4 gram/day) up until 24 hours of a scheduled assessment visit during the 12-week treatment period. The estimates shown are the Kaplan-Meier estimates of the proportion of participants that took rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment of Response to Treatment on Day 4</measure>
    <time_frame>Day 4</time_frame>
    <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment of Response to Treatment at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment of Response to Treatment at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment of Response to Treatment at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment of Response to Treatment at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Physician's Global Assessment of Response to Treatment at Day 4</measure>
    <time_frame>Day 4</time_frame>
    <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Physician's Global Assessment of Response to Treatment at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Physician's Global Assessment of Response to Treatment at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Physician's Global Assessment of Response to Treatment at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Physician's Global Assessment of Response to Treatment at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration of Canakinumab (Cmax)</measure>
    <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Observed Plasma Concentration of Canakinumab (Tmax)</measure>
    <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve up to the Last Measurable Concentration (AUClast)</measure>
    <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve From Time Zero to Infinity AUC(0-inf)</measure>
    <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Half-life (t1/2) of Canakinumab</measure>
    <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
    <description>The time it takes for the concentration level of canakinumab to fall to 50% of the original value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance of Canakinumab From Plasma (CL/F)</measure>
    <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During Terminal Phase (Vz/F)</measure>
    <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Part A: Canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this ascending dose part, participants received a single intra-articular injection of canakinumab. The beginning dose was 150 mg, escalating to the 300 mg dose and then to 600 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received a single intra-articular injection of canakinumab-matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single intra-articular injection of canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Canakinumab</intervention_name>
    <description>Intra-articular injection</description>
    <arm_group_label>Part A: Canakinumab</arm_group_label>
    <arm_group_label>Part B: Canakinumab</arm_group_label>
    <other_name>ACZ885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to canakinumab</intervention_name>
    <description>Intra-articular injection</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_label>Part B: Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Tablets for oral administration</description>
    <arm_group_label>Part B: Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Naproxen</intervention_name>
    <description>Tablets for oral administration</description>
    <arm_group_label>Part B: Canakinumab</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent must be obtained before any assessment is performed.

          2. Male and female patients aged 40 - 80 years (inclusive).

          3. Diagnosis of knee osteoarthritis

          4. Radiographic evidence of tibiofemoral compartment osteoarthritis

          5. Pain in the knee during the last 24 hours.The patients should also have had pain in
             the affected knee on most days over the last month.

          6. Patients who are willing to discontinue all non-steroidal anti-inflammatory drugs
             (NSAIDs) or other analgesic medication taken for any condition, including their knee
             pain,

          7. Patients who are on stable dose of opioids for at least 1 month before screening can
             continue to take their opioid at this stable dose throughout the study.

          8. Patients must also be willing to abstain from any intra-articular or peri-articular
             injections to the knee or surgery during the treatment period

          9. Patients who, if they are currently taking aspirin (325 mg/day or less; as
             anti-coagulants), are willing to remain on a stable dose one month prior to screening
             and throughout the study

        Exclusion Criteria:

          1. Subjects with known hypersensitivity to any biological or investigational drugs.

          2. Patients with contraindications to knee injections

          3. Patients with joint effusion

          4. Patients should not have rheumatoid arthritis or any connective tissue like disease

          5. Secondary osteoarthritis with history and/or any evidence of the following diseases:
             septic arthritis, inflammatory joint disease, gout, Paget's disease of the bone,
             articular fracture, major dysplasias or congenital abnormality, ochronosis,
             acromegaly, hemochromatosis, Wilson's disease, primary osteochondromatosis, juvenile
             chronic arthritis with continued activity in adulthood, heritable disorders (e.g.
             hypermobility). Patients with secondary osteoarthritis following menisectomy or
             injuries of a collateral or cruciate ligament are not excluded.

          6. Presence or history of underlying metabolic, endocrine, hematologic, pulmonary,
             cardiac, blood, renal, hepatic, infectious, psychiatric or gastrointestinal conditions

          7. Evidence of tuberculosis (TB)

          8. One of the risk factors for TB such as:

               1. Substance abuse (e.g. injection or non-injection)

               2. Health-care workers with unprotected exposure to patients who are at high risk of
                  TB

               3. Patients with TB disease before the identification and correct airborne
                  precautions of the patient

               4. close contact (i.e. share the same air space in a household or other enclosed
                  environment for a prolonged period (days or weeks, not minutes or hours)) with a
                  person with active pulmonary TB disease.

          9. Significant medical problems, including but not limited to the following: uncontrolled
             hypertension,congestive heart failure, uncontrolled diabetes type I and II

         10. Subjects with evidence of hepatic or blood coagulation disorders (i.e. hemophilia,
             etc), anemia, idiopathic thrombocytopenic purpura, or gastrointestinal disorder:
             severe hepatic disease, history of alcohol and drug abuse; disease of gall bladder and
             pancreas; active peptic ulceration, gastrointestinal bleeding or history of severe
             gastro-esophageal reflux disease or severe hiatus hernia; inflammatory bowel disease.

         11. Use of any therapeutic protein drug (e.g. anti-tumor necrosis factor alpha (TNFα)
             antibody)

         12. Presence of severe renal function impairment. History of renal trauma,
             glomerulonephritis, patients with one kidney, or renal failure requiring regular
             dialysis treatment.

         13. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive pregnancy test (serum or urine).

         14. Subjects with known contra-indications to naproxen (e.g. heart or circulation
             problems, history of ulcer disease etc.), analgesics, antipyretics, or NSAIDs.

         15. Disease of the spine or other lower extremity joints which may interfere with the
             assessment of the target joint.

         16. Surgery on the knee within the last year. Observational arthroscopy, arthroscopic
             surgery or lavage of the knee within the last 6 months.

         17. Use of assistive devices other than a cane (walking stick) or knee brace.

         18. Subjects who have experienced, any time in the past, asthma, acute rhinitis, nasal
             polyps, angioneurotic edema, urticaria or other allergic-type reaction after taking
             acetylsalicylic acid (ASA)/ aspirin or NSAIDs.

         19. Any history of prior peptic ulcer disease or prior NSAID gastrointestinal
             complications for the past 5 years.

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research, PLLC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Arthritis &amp; Osteoporosis Medical Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westlake Medical Research</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush-Presbyterian St. Lukes Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinical Research Institute</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <results_first_submitted>July 26, 2012</results_first_submitted>
  <results_first_submitted_qc>July 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2012</results_first_posted>
  <last_update_submitted>September 28, 2012</last_update_submitted>
  <last_update_submitted_qc>September 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteo arthritis</keyword>
  <keyword>pain control</keyword>
  <keyword>intra- articular injections</keyword>
  <keyword>Knee OA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part A: Canakinumab 150 mg</title>
          <description>Participants received a single intra-articular injection of 150 mg canakinumab.</description>
        </group>
        <group group_id="P2">
          <title>Part A: Canakinumab 300 mg</title>
          <description>Participants received a single intra-articular injection of 300 mg canakinumab.</description>
        </group>
        <group group_id="P3">
          <title>Part A: Canakinumab 600 mg</title>
          <description>Participants received a single intra-articular injection of 600 mg canakinumab.</description>
        </group>
        <group group_id="P4">
          <title>Part A: Placebo</title>
          <description>Participants received a single intra-articular injection of canakinumab-matching placebo.</description>
        </group>
        <group group_id="P5">
          <title>Part B: Canakinumab</title>
          <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Part B: Placebo</title>
          <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Part B: Naproxen</title>
          <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="47"/>
                <participants group_id="P7" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="40"/>
                <participants group_id="P7" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A: Canakinumab 150 mg</title>
          <description>Participants received a single intra-articular injection of 150 mg canakinumab.</description>
        </group>
        <group group_id="B2">
          <title>Part A: Canakinumab 300 mg</title>
          <description>Participants received a single intra-articular injection of 300 mg canakinumab.</description>
        </group>
        <group group_id="B3">
          <title>Part A: Canakinumab 600 mg</title>
          <description>Participants received a single intra-articular injection of 600 mg canakinumab.</description>
        </group>
        <group group_id="B4">
          <title>Part A: Placebo</title>
          <description>Participants received a single intra-articular injection of canakinumab-matching placebo.</description>
        </group>
        <group group_id="B5">
          <title>Part B: Canakinumab</title>
          <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Part B: Placebo</title>
          <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Part B: Naproxen</title>
          <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="45"/>
            <count group_id="B6" value="47"/>
            <count group_id="B7" value="53"/>
            <count group_id="B8" value="169"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="12.79"/>
                    <measurement group_id="B2" value="61.0" spread="9.63"/>
                    <measurement group_id="B3" value="64.2" spread="10.68"/>
                    <measurement group_id="B4" value="57.8" spread="7.76"/>
                    <measurement group_id="B5" value="NA">Age demographic data for Study Part A.</measurement>
                    <measurement group_id="B6" value="NA">Age demographic data for Study Part A.</measurement>
                    <measurement group_id="B7" value="NA">Age demographic data for Study Part A.</measurement>
                    <measurement group_id="B8" value="60.5" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Age demographic data for Study Part B.</measurement>
                    <measurement group_id="B2" value="NA">Age demographic data for Study Part B.</measurement>
                    <measurement group_id="B3" value="NA">Age demographic data for Study Part B.</measurement>
                    <measurement group_id="B4" value="NA">Age demographic data for Study Part B.</measurement>
                    <measurement group_id="B5" value="61.4" spread="8.96"/>
                    <measurement group_id="B6" value="60.3" spread="9.71"/>
                    <measurement group_id="B7" value="62.2" spread="8.10"/>
                    <measurement group_id="B8" value="61.3" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part A: Number of Participants With Intolerance Events</title>
        <description>An intolerance event is defined as an acute inflammatory reaction, characterized by a 30 mm increase in pain (on a 100 mm visual analog scale (VAS) and associated with a new or worsened synovial fluid effusion within 3 days following the intra-articular (i.a.) injection. If baseline VAS pain score is ≥ 70 mm, an intolerance event is defined as an increase in pain by 20 mm on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection. If baseline VAS pain score is ≥ 80 mm, an intolerance event is defined as an increase in pain by 10 mm on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection. If baseline pain score is ≥ 90 mm, an intolerance event is defined as the patients experiencing an unspecified increase in pain on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection.</description>
        <time_frame>Baseline to Day 3</time_frame>
        <population>Safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Canakinumab 150 mg</title>
            <description>Participants received a single intra-articular injection of 150 mg canakinumab.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Canakinumab 300 mg</title>
            <description>Participants received a single intra-articular injection of 300 mg canakinumab.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Canakinumab 600 mg</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab.</description>
          </group>
          <group group_id="O4">
            <title>Part A: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab-matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Intolerance Events</title>
          <description>An intolerance event is defined as an acute inflammatory reaction, characterized by a 30 mm increase in pain (on a 100 mm visual analog scale (VAS) and associated with a new or worsened synovial fluid effusion within 3 days following the intra-articular (i.a.) injection. If baseline VAS pain score is ≥ 70 mm, an intolerance event is defined as an increase in pain by 20 mm on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection. If baseline VAS pain score is ≥ 80 mm, an intolerance event is defined as an increase in pain by 10 mm on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection. If baseline pain score is ≥ 90 mm, an intolerance event is defined as the patients experiencing an unspecified increase in pain on a 100 mm VAS associated with new or worsened synovial fluid effusion within 3 days following the i.a. injection.</description>
          <population>Safety analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline to Day 4 in Pain Using 100 mm Visual Analog Scale (VAS)</title>
        <description>After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm). A negative change from Baseline score indicates improvement.
Results are from a Bayesian analysis of covariance (ANCOVA) model, fitting baseline pain VAS score as a covariate, time by treatment as fixed effects, region and subject as random effects.</description>
        <time_frame>Baseline and Day 4</time_frame>
        <population>Pharmacodynamic (PD) analysis set - Patients with any available PD data and no major protocol deviations with impact on PD data, and where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline to Day 4 in Pain Using 100 mm Visual Analog Scale (VAS)</title>
          <description>After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm). A negative change from Baseline score indicates improvement.
Results are from a Bayesian analysis of covariance (ANCOVA) model, fitting baseline pain VAS score as a covariate, time by treatment as fixed effects, region and subject as random effects.</description>
          <population>Pharmacodynamic (PD) analysis set - Patients with any available PD data and no major protocol deviations with impact on PD data, and where data were available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.7" spread="4.05"/>
                    <measurement group_id="O2" value="-26.5" spread="3.97"/>
                    <measurement group_id="O3" value="-27.6" spread="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Change From Baseline to Week 4 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale</title>
        <description>The Western Ontario and McMaster osteoarthritis Index (WOMAC) pain subscale asks patients to rate pain in the index knee joint in the last 48 hours doing different activities on a scale from none (0) to extreme pain (4). The answers are summed and the total pain subscale score ranges from 0 to 20, where higher scores indicate more pain. A negative change from Baseline score indicates improvement.
Results are from a Bayesian ANCOVA model, fitting baseline WOMAC pain score as a covariate, time by treatment as fixed effects, region and patient as random effects.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Pharmacodynamic (PD) analysis set - Patients with any available PD data and no major protocol deviations with impact on PD data, and where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline to Week 4 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale</title>
          <description>The Western Ontario and McMaster osteoarthritis Index (WOMAC) pain subscale asks patients to rate pain in the index knee joint in the last 48 hours doing different activities on a scale from none (0) to extreme pain (4). The answers are summed and the total pain subscale score ranges from 0 to 20, where higher scores indicate more pain. A negative change from Baseline score indicates improvement.
Results are from a Bayesian ANCOVA model, fitting baseline WOMAC pain score as a covariate, time by treatment as fixed effects, region and patient as random effects.</description>
          <population>Pharmacodynamic (PD) analysis set - Patients with any available PD data and no major protocol deviations with impact on PD data, and where data were available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="0.71"/>
                    <measurement group_id="O2" value="-4.0" spread="0.68"/>
                    <measurement group_id="O3" value="-4.5" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in Pain Using 100 mm Visual Analog Scale (VAS)</title>
        <description>After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm).
Results are from a Bayesian ANCOVA model, fitting baseline pain VAS score as a covariate, time by treatment as fixed effects, region and patient as random effects.</description>
        <time_frame>Baseline and Weeks 4, 8 and 12</time_frame>
        <population>Pharmacodynamic (PD) analysis set - Patients with any available PD data and no major protocol deviations with impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in Pain Using 100 mm Visual Analog Scale (VAS)</title>
          <description>After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm).
Results are from a Bayesian ANCOVA model, fitting baseline pain VAS score as a covariate, time by treatment as fixed effects, region and patient as random effects.</description>
          <population>Pharmacodynamic (PD) analysis set - Patients with any available PD data and no major protocol deviations with impact on PD data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.6" spread="4.03"/>
                    <measurement group_id="O2" value="-31.1" spread="4.03"/>
                    <measurement group_id="O3" value="-36.1" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.2" spread="4.12"/>
                    <measurement group_id="O2" value="-30.9" spread="4.06"/>
                    <measurement group_id="O3" value="-33.0" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.1" spread="4.14"/>
                    <measurement group_id="O2" value="-32.1" spread="4.06"/>
                    <measurement group_id="O3" value="-27.8" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Percentage of Responders in the Pain 100 mm Visual Analog Scale (VAS)</title>
        <description>A responder is defined as a participant with a 50% or greater reduction from baseline on the VAS scale for pain assessment. After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm).</description>
        <time_frame>Baseline, Day 4, Weeks 1, 2, 4, 8 and 12</time_frame>
        <population>Pharmacodynamic (PD) analysis set - Patients with any available PD data and no major protocol deviations with impact on PD data. N is the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Percentage of Responders in the Pain 100 mm Visual Analog Scale (VAS)</title>
          <description>A responder is defined as a participant with a 50% or greater reduction from baseline on the VAS scale for pain assessment. After walking for 20 meters, participants were asked to assess the pain in their affected knee on a 100 mm linear visual analog scale ranging from no pain (0 mm) to unbearable pain (100 mm).</description>
          <population>Pharmacodynamic (PD) analysis set - Patients with any available PD data and no major protocol deviations with impact on PD data. N is the number of participants with available data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4 [N=42, 44, 48]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="43.2"/>
                    <measurement group_id="O3" value="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 [N=42, 44, 48]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5"/>
                    <measurement group_id="O2" value="45.5"/>
                    <measurement group_id="O3" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 [N=41, 44, 48]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3"/>
                    <measurement group_id="O2" value="43.2"/>
                    <measurement group_id="O3" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 [N=39, 40, 46]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3"/>
                    <measurement group_id="O2" value="55.0"/>
                    <measurement group_id="O3" value="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [N=36, 38, 43]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 [N=35, 37, 41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6"/>
                    <measurement group_id="O2" value="51.4"/>
                    <measurement group_id="O3" value="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Change From Baseline in WOMAC Pain, Stiffness and Physical Function Subscales</title>
        <description>The WOMAC consists of 3 subscales:
The Pain subscale asks patients to rate pain in the index knee joint in the last 48 hours during walking, using stairs, in bed, sitting or lying, and standing on a scale from none (0) to extreme pain (4). The answers are summed and the total pain subscale score ranges from 0-20.
The Stiffness subscale assesses stiffness in the index knee joint during the last 48 hours doing different activities on a scale from none (0) to extreme stiffness (4). The total stiffness subscale score ranges from 0-8.
The Physical Function subscale assesses difficulty performing daily physical activities during the last 48 hours on a scale from none (0) to extreme difficulty (4). The total physical function subscale score ranges from 0-68.
Higher scores indicate more pain/stiffness/difficulty. Results are from a Bayesian ANCOVA model, with baseline WOMAC score as a covariate, time by treatment as fixed effects, region and patient as random effects.</description>
        <time_frame>Baseline and Weeks 4, 8 and 12</time_frame>
        <population>Pharmacodynamic (PD) analysis set - Patients with any available PD data and no major protocol deviations with impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Change From Baseline in WOMAC Pain, Stiffness and Physical Function Subscales</title>
          <description>The WOMAC consists of 3 subscales:
The Pain subscale asks patients to rate pain in the index knee joint in the last 48 hours during walking, using stairs, in bed, sitting or lying, and standing on a scale from none (0) to extreme pain (4). The answers are summed and the total pain subscale score ranges from 0-20.
The Stiffness subscale assesses stiffness in the index knee joint during the last 48 hours doing different activities on a scale from none (0) to extreme stiffness (4). The total stiffness subscale score ranges from 0-8.
The Physical Function subscale assesses difficulty performing daily physical activities during the last 48 hours on a scale from none (0) to extreme difficulty (4). The total physical function subscale score ranges from 0-68.
Higher scores indicate more pain/stiffness/difficulty. Results are from a Bayesian ANCOVA model, with baseline WOMAC score as a covariate, time by treatment as fixed effects, region and patient as random effects.</description>
          <population>Pharmacodynamic (PD) analysis set - Patients with any available PD data and no major protocol deviations with impact on PD data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="0.72"/>
                    <measurement group_id="O2" value="-4.2" spread="0.69"/>
                    <measurement group_id="O3" value="-4.6" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="0.72"/>
                    <measurement group_id="O2" value="-4.5" spread="0.69"/>
                    <measurement group_id="O3" value="-4.0" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.36"/>
                    <measurement group_id="O2" value="-1.5" spread="0.36"/>
                    <measurement group_id="O3" value="-1.9" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.37"/>
                    <measurement group_id="O2" value="-1.5" spread="0.36"/>
                    <measurement group_id="O3" value="-2.0" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.37"/>
                    <measurement group_id="O2" value="-1.7" spread="0.37"/>
                    <measurement group_id="O3" value="-1.4" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Function at Week 4 [N=38, 39, 43]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.1" spread="1.93"/>
                    <measurement group_id="O2" value="-15.9" spread="1.93"/>
                    <measurement group_id="O3" value="-16.2" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Function at Week 8 [N=35, 36, 41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" spread="1.97"/>
                    <measurement group_id="O2" value="-14.9" spread="1.94"/>
                    <measurement group_id="O3" value="-16.1" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Function at Week 12 [N= 33, 36, 39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" spread="2.01"/>
                    <measurement group_id="O2" value="-16.5" spread="1.96"/>
                    <measurement group_id="O3" value="-14.4" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Proportion of Participants Who Used Rescue Analgesic During Study</title>
        <description>Participants were permitted to take oral rescue medication (Acetaminophen ≤ 4 gram/day) up until 24 hours of a scheduled assessment visit during the 12-week treatment period. The estimates shown are the Kaplan-Meier estimates of the proportion of participants that took rescue medication.</description>
        <time_frame>Day 4, Weeks 1, 2, 4, 8 and 12</time_frame>
        <population>Safety analysis set (all participants as assigned that received at least one dose of study drug).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Proportion of Participants Who Used Rescue Analgesic During Study</title>
          <description>Participants were permitted to take oral rescue medication (Acetaminophen ≤ 4 gram/day) up until 24 hours of a scheduled assessment visit during the 12-week treatment period. The estimates shown are the Kaplan-Meier estimates of the proportion of participants that took rescue medication.</description>
          <population>Safety analysis set (all participants as assigned that received at least one dose of study drug).</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27"/>
                    <measurement group_id="O2" value="0.30"/>
                    <measurement group_id="O3" value="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45"/>
                    <measurement group_id="O2" value="0.47"/>
                    <measurement group_id="O3" value="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52"/>
                    <measurement group_id="O2" value="0.57"/>
                    <measurement group_id="O3" value="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55"/>
                    <measurement group_id="O2" value="0.60"/>
                    <measurement group_id="O3" value="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57"/>
                    <measurement group_id="O2" value="0.69"/>
                    <measurement group_id="O3" value="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62"/>
                    <measurement group_id="O2" value="0.75"/>
                    <measurement group_id="O3" value="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient’s Global Assessment of Response to Treatment on Day 4</title>
        <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
        <time_frame>Day 4</time_frame>
        <population>Pharmacodynamic analysis set, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient’s Global Assessment of Response to Treatment on Day 4</title>
          <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
          <population>Pharmacodynamic analysis set, where data were available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Assessment of Response to Treatment at Week 2</title>
        <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
        <time_frame>Week 2</time_frame>
        <population>Pharmacodynamic analysis set, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Assessment of Response to Treatment at Week 2</title>
          <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
          <population>Pharmacodynamic analysis set, where data were available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Assessment of Response to Treatment at Week 4</title>
        <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
        <time_frame>Week 4</time_frame>
        <population>Pharmacodynamic analysis set, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Assessment of Response to Treatment at Week 4</title>
          <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
          <population>Pharmacodynamic analysis set, where data were available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Assessment of Response to Treatment at Week 8</title>
        <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
        <time_frame>Week 8</time_frame>
        <population>Pharmacodynamic analysis set, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Assessment of Response to Treatment at Week 8</title>
          <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
          <population>Pharmacodynamic analysis set, where data were available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Assessment of Response to Treatment at Week 12</title>
        <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
        <time_frame>Week 12</time_frame>
        <population>Pharmacodynamic analysis set, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Assessment of Response to Treatment at Week 12</title>
          <description>Participants made a global assessment of their response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
          <population>Pharmacodynamic analysis set, where data were available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Physician's Global Assessment of Response to Treatment at Day 4</title>
        <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
        <time_frame>Day 4</time_frame>
        <population>Pharmacodynamic analysis set, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Physician's Global Assessment of Response to Treatment at Day 4</title>
          <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
          <population>Pharmacodynamic analysis set, where data were available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Physician's Global Assessment of Response to Treatment at Week 2</title>
        <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
        <time_frame>Week 2</time_frame>
        <population>Pharmacodynamic analysis set, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Physician's Global Assessment of Response to Treatment at Week 2</title>
          <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
          <population>Pharmacodynamic analysis set, where data were available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Physician's Global Assessment of Response to Treatment at Week 4</title>
        <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
        <time_frame>Week 4</time_frame>
        <population>Pharmacodynamic analysis set, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Physician's Global Assessment of Response to Treatment at Week 4</title>
          <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
          <population>Pharmacodynamic analysis set, where data were available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Physician's Global Assessment of Response to Treatment at Week 8</title>
        <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
        <time_frame>Week 8</time_frame>
        <population>Pharmacodynamic analysis set, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Physician's Global Assessment of Response to Treatment at Week 8</title>
          <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
          <population>Pharmacodynamic analysis set, where data were available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Physician's Global Assessment of Response to Treatment at Week 12</title>
        <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
        <time_frame>Week 12</time_frame>
        <population>Pharmacodynamic analysis set, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Placebo</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Naproxen</title>
            <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Physician's Global Assessment of Response to Treatment at Week 12</title>
          <description>The study physician made a global assessment of response to treatment using a 5-point Likert scale: Excellent, Good, Acceptable, Poor, Very Poor.</description>
          <population>Pharmacodynamic analysis set, where data were available.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration of Canakinumab (Cmax)</title>
        <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
        <population>Pharmacokinetic analysis set where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Canakinumab 150 mg</title>
            <description>Participants received a single intra-articular injection of 150 mg canakinumab.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Canakinumab 300 mg</title>
            <description>Participants received a single intra-articular injection of 300 mg canakinumab.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Canakinumab 600 mg</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration of Canakinumab (Cmax)</title>
          <population>Pharmacokinetic analysis set where data were available.</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" spread="8.54"/>
                    <measurement group_id="O2" value="34.8" spread="11.3"/>
                    <measurement group_id="O3" value="65.5" spread="14.5"/>
                    <measurement group_id="O4" value="77.8" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Maximum Observed Plasma Concentration of Canakinumab (Tmax)</title>
        <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
        <population>Pharmacokinetic analysis set where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Canakinumab 150 mg</title>
            <description>Participants received a single intra-articular injection of 150 mg canakinumab.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Canakinumab 300 mg</title>
            <description>Participants received a single intra-articular injection of 300 mg canakinumab.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Canakinumab 600 mg</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Observed Plasma Concentration of Canakinumab (Tmax)</title>
          <population>Pharmacokinetic analysis set where data were available.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" lower_limit="74.6" upper_limit="164"/>
                    <measurement group_id="O2" value="86.7" lower_limit="71.8" upper_limit="174"/>
                    <measurement group_id="O3" value="144" lower_limit="71.5" upper_limit="197"/>
                    <measurement group_id="O4" value="95.9" lower_limit="46.3" upper_limit="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve up to the Last Measurable Concentration (AUClast)</title>
        <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
        <population>Pharmacokinetic analysis set where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Canakinumab 150 mg</title>
            <description>Participants received a single intra-articular injection of 150 mg canakinumab.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Canakinumab 300 mg</title>
            <description>Participants received a single intra-articular injection of 300 mg canakinumab.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Canakinumab 600 mg</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve up to the Last Measurable Concentration (AUClast)</title>
          <population>Pharmacokinetic analysis set where data were available.</population>
          <units>µg*day/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16900" spread="4430"/>
                    <measurement group_id="O2" value="30700" spread="8380"/>
                    <measurement group_id="O3" value="56100" spread="23900"/>
                    <measurement group_id="O4" value="71900" spread="23800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve From Time Zero to Infinity AUC(0-inf)</title>
        <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
        <population>Pharmacokinetic analysis set where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Canakinumab 150 mg</title>
            <description>Participants received a single intra-articular injection of 150 mg canakinumab.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Canakinumab 300 mg</title>
            <description>Participants received a single intra-articular injection of 300 mg canakinumab.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Canakinumab 600 mg</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve From Time Zero to Infinity AUC(0-inf)</title>
          <population>Pharmacokinetic analysis set where data were available.</population>
          <units>µg*day/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16900" spread="4780"/>
                    <measurement group_id="O2" value="32400" spread="8010"/>
                    <measurement group_id="O3" value="49300" spread="16100"/>
                    <measurement group_id="O4" value="78300" spread="28000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Half-life (t1/2) of Canakinumab</title>
        <description>The time it takes for the concentration level of canakinumab to fall to 50% of the original value.</description>
        <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
        <population>Pharmacokinetic analysis set where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Canakinumab 150 mg</title>
            <description>Participants received a single intra-articular injection of 150 mg canakinumab.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Canakinumab 300 mg</title>
            <description>Participants received a single intra-articular injection of 300 mg canakinumab.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Canakinumab 600 mg</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Half-life (t1/2) of Canakinumab</title>
          <description>The time it takes for the concentration level of canakinumab to fall to 50% of the original value.</description>
          <population>Pharmacokinetic analysis set where data were available.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="539" spread="47.1"/>
                    <measurement group_id="O2" value="578" spread="145"/>
                    <measurement group_id="O3" value="474" spread="93.6"/>
                    <measurement group_id="O4" value="736" spread="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance of Canakinumab From Plasma (CL/F)</title>
        <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
        <population>Pharmacokinetic analysis set, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Canakinumab 150 mg</title>
            <description>Participants received a single intra-articular injection of 150 mg canakinumab.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Canakinumab 300 mg</title>
            <description>Participants received a single intra-articular injection of 300 mg canakinumab.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Canakinumab 600 mg</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance of Canakinumab From Plasma (CL/F)</title>
          <population>Pharmacokinetic analysis set, where data were available.</population>
          <units>mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.58" spread="3.08"/>
                    <measurement group_id="O2" value="9.66" spread="2.03"/>
                    <measurement group_id="O3" value="13.3" spread="4.27"/>
                    <measurement group_id="O4" value="8.65" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During Terminal Phase (Vz/F)</title>
        <time_frame>Day 1, pre-dose and 1, 3, 6 and 8 hours post-dose (Part A only), Day 2, 4, 8, 15, 29, 57, 85 and 126.</time_frame>
        <population>Pharmacokinetic analysis set, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Canakinumab 150 mg</title>
            <description>Participants received a single intra-articular injection of 150 mg canakinumab.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Canakinumab 300 mg</title>
            <description>Participants received a single intra-articular injection of 300 mg canakinumab.</description>
          </group>
          <group group_id="O3">
            <title>Part A: Canakinumab 600 mg</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Canakinumab</title>
            <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During Terminal Phase (Vz/F)</title>
          <population>Pharmacokinetic analysis set, where data were available.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7320" spread="1870"/>
                    <measurement group_id="O2" value="8060" spread="2830"/>
                    <measurement group_id="O3" value="8930" spread="3000"/>
                    <measurement group_id="O4" value="8910" spread="4070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Part A: Canakinumab 150 mg</title>
          <description>Participants received a single intra-articular injection of 150 mg canakinumab.</description>
        </group>
        <group group_id="E2">
          <title>Part A: Canakinumab 300 mg</title>
          <description>Participants received a single intra-articular injection of 300 mg canakinumab.</description>
        </group>
        <group group_id="E3">
          <title>Part A: Canakinumab 600 mg</title>
          <description>Participants received a single intra-articular injection of 600 mg canakinumab.</description>
        </group>
        <group group_id="E4">
          <title>Part A: Placebo</title>
          <description>Participants received a single intra-articular injection of canakinumab-matching placebo.</description>
        </group>
        <group group_id="E5">
          <title>Part B: Canakinumab</title>
          <description>Participants received a single intra-articular injection of 600 mg canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Part B: Placebo</title>
          <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Part B: Naproxen</title>
          <description>Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

